Revenues of USD 73 million and an Adjusted EBITDA of USD 21 million
Aker BioMarine has reported revenues of USD 73 million and an Adjusted EBITDA of USD 21 million for the second quarter of 2022. The company confirmed these data have been especially driven by high sales volumes and prices for Qrill Aqua.
Other highlights of the second quarter are a net profit of USD 15 million, up from USD -3 million the same quarter last and the highest second quarter ever offshore production volume at 16,500 tons (up 19% from the same quarter last year). In addition, an 8% more sales ingredients segment compared to the same quarter last year.
Regarding this Matts Johansen, CEO of Aker BioMarine said: “So far this year Antarctic production of krill meal is 39,000 tons, 13% above last year. The Superba krill oil sales organization is strengthened in all geographies. It will execute on the upgraded pipeline to deliver growth. We reiterate our financial targets for the full year 2022”.
Aker BioMarine reiterates its targets for 2022 with a sales growth of between 20-25%. Also, an Adjusted EBITDA margin of 20-25%.
About Aker BioMarine ASA
Aker BioMarine ASA is a leading biotech innovator and Antarctic krill-harvesting company. It develops krill-derived products for pharma, consumer health, and wellness as well as animal nutrition.
The company has a strong position in its industry and is the world’s leading supplier of krill, the natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica.
Near a month ago, the company received FDA approval for its QRILL Aqua in the United States.
